Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- DSP to Boost Domestic CNS Business for Early Maximization of Lonasen
November 1, 2011
- Shionogi’s Strength in Japan Weakened by Slack US Results, Overall Sales Down 13.5% in Apr-Sept
November 1, 2011
- Sharp Decrease in Profits due to Declines in License Revenues: JCR’s Half year Financial Report
November 1, 2011
- Zeria Upwardly Revises Profits forecasts for 1st Half of FY2012
November 1, 2011
- Mochida: Epadel, Lexapro Drive Growth in 1st-Half Sales and Profits
November 1, 2011
- DSP: Strong Yen Contributes to 5.6% Decline in Sales
November 1, 2011
- Further Deterioration in Sales Prices Unlikely in 2nd Half: President Watanabe of Mediceo
November 1, 2011
- Three Top Dispensing Pharmacy Chains Report 50% Growth in Operating Profits
November 1, 2011
- ASKA Downwardly Revises Sales Forecast Due to Effects of Quake
October 31, 2011
- Astellas Upwardly Revises Business Forecasts Driven by Vesicare
October 31, 2011
- Abilify Posted US Sales of US$983 Mil. in Jul-Sep
October 31, 2011
- Anti-HIV JTK-303 Applied for Combination Tablet in the US: JT
October 31, 2011
- Losses Increase Due to Fallen Milestone Payments: OncoTherapy
October 31, 2011
- Wakamoto’s Apr-Sep Profits Up 2% on Latanoprost Sales Growth, Recovered Losses
October 31, 2011
- Terumo Posts Record Sales, Operating Profits in First Half FY2012
October 31, 2011
- PI Trial of Darinaparsin Inj. Starts for PTCL: Solasia
October 31, 2011
- MediciNova to Start Repeat Dose PIb Clinical Trial of MN-221 in US
October 31, 2011
- Meiji Seika Pharma Planning to Develop Biosimilars for Infectious Diseases, Cancer, and RA
October 31, 2011
- Medipal HD: Near 90% Decline in Operating Profits
October 31, 2011
- Kyowa Kirin’s Pharmaceutical Business Reports Increases in Sales, Profits in Jan.-Sept. Driven by Nesp
October 28, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…